Xie, Junqing http://orcid.org/0000-0002-0040-0042
Mothe, Beatriz http://orcid.org/0000-0001-9975-407X
Alcalde Herraiz, Marta
Li, Chunxiao
Xu, Yu http://orcid.org/0000-0002-7304-5045
Jödicke, Annika M.
Gao, Yaqing
Wang, Yunhe
Feng, Shuo http://orcid.org/0000-0001-7855-0991
Wei, Jia http://orcid.org/0000-0001-9621-529X
Chen, Zhuoyao http://orcid.org/0000-0003-4201-4649
Hong, Shenda http://orcid.org/0000-0001-7521-5127
Wu, Yeda http://orcid.org/0000-0002-5977-1526
Su, Binbin
Zheng, Xiaoying
Cohet, Catherine http://orcid.org/0000-0002-0022-7251
Ali, Raghib
Wareham, Nick http://orcid.org/0000-0003-1422-2993
Alhambra, Daniel Prieto http://orcid.org/0000-0002-3950-6346
Article History
Received: 8 September 2023
Accepted: 29 April 2024
First Online: 13 May 2024
Competing interests
: DPA’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA’s department. The remaining authors declare no competing interests.